Clinical diagnosis and treatment of immune checkpoint inhibitors‐related endocrine dysfunction

As a new class of antitumor drugs, immune checkpoint inhibitors (ICIs) have shown remarkable efficacy toward the treatment of various malignant tumors. By virtue of their targets and mechanisms of action, ICIs can cause autoimmune and inflammatory effects, termed as immune‐related adverse events (ir...

Descripción completa

Detalles Bibliográficos
Autores principales: Duan, Lian, Wang, Linjie, Wang, Hanping, Si, Xiaoyan, Zhang, Li, Liu, Xiaowei, Li, Yue, Guo, Xiaoxiao, Zhou, Jiaxin, Zhu, Huijuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2020
Materias:
Clinical Guideline
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7113039/
https://www.ncbi.nlm.nih.gov/pubmed/32043816
http://dx.doi.org/10.1111/1759-7714.13347

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7113039/
https://www.ncbi.nlm.nih.gov/pubmed/32043816
http://dx.doi.org/10.1111/1759-7714.13347

Ejemplares similares